Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

Purpose

Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy. This study will have 5 treatment arms (4 active and 1 placebo).

Condition

  • Atopic Dermatitis

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Male or female patients with a clinical diagnosis of AD for at least 1 year; 2. vIGA score of ≥3 at Screening and Baseline; 3. ≥10% BSA of AD involvement at Screening and Baseline; 4. EASI score ≥16 at Screening and Baseline; 5. History of inadequate response to treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI); 6. Twice daily application of a consistent amount of topical emollient for at least 7 days prior to randomization.

Exclusion Criteria

  1. Immunosuppressive/immunomodulating drugs, systemic therapies or phototherapy within 4 weeks prior to randomization; 2. Treatment with leukotriene inhibitors within 4 weeks prior to randomization; 3. Treatment with topical therapies (including TCS, TCI, topical phosphodiesterase inhibitors, topical JAK inhibitors) or prescription moisturizers, within 1 week prior to randomization; 4. Previous treatment at any time prior to randomization with monoclonal antibody / biologic therapeutic agents as follows; 1. Prior exposure to dupilumab (Dupixent®) which was discontinued due to lack of efficacy, loss of response, or adverse event; 2. Investigational or approved agents targeting interleukins IL-4 or IL-13 ligands or receptors of IL-4 or IL-13, including but not limited to lebrikizumab, tralokinumab or ASLAN004; 3. Other investigational or approved biologic drug within 16 weeks or within 5 half-lives (if known), whichever is longer, prior to the Baseline visit; 4. Cell-depleting biologics, including, but not limited to, rituximab within 6 months prior to the Baseline visit; 5. Inadequate organ function, abnormal lab result, uncontrolled blood pressure or other health condition considered clinically significant by the investigator at the Screening visit; 6. History of HIV, Hepatitis B, Hepatitis C or active/latent Tuberculosis infection; 7. History of immunosuppression including history of invasive opportunistic infections; 8. Treatment with live attenuated vaccine within 8 weeks prior to randomization; 9. Parasitic infection within 4 weeks prior to baseline travel within 3 months prior to randomization to areas of high parasitic exposure; 10. Have skin comorbidities that in the opinion of the Investigator may interfere with study assessments; 11. Pregnant or breastfeeding women; 12. Patients unwilling to use adequate birth control. 13. Active COVID infection at baseline.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Placebo Comparator
Placebo every two weeks (q2w)
Placebo q2w - placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every 2 weeks (q2w) from Week 2 to Week 14.
  • Drug: Placebo
    Sterile solution for subcutaneous injection
Experimental
ASLAN004 300 mg q2w
ASLAN004 300 mg q2w - loading doses at Baseline and Week 1, followed by regular doses of 300mg q2w from Week 2 to Week 14.
  • Biological: ASLAN004
    Sterile solution for subcutaneous injection
Experimental
ASLAN004 400 mg q2w
ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14.
  • Biological: ASLAN004
    Sterile solution for subcutaneous injection
Experimental
ASLAN004 400 mg every four weeks (q4w)
ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14.
  • Biological: ASLAN004
    Sterile solution for subcutaneous injection
    Other names:
    • Placebo
Experimental
ASLAN004 600 mg q4w
ASLAN004 600 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 600 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14.
  • Biological: ASLAN004
    Sterile solution for subcutaneous injection
    Other names:
    • Placebo

Recruiting Locations

More Details

NCT ID
NCT05158023
Status
Completed
Sponsor
ASLAN Pharmaceuticals